Transdiagnostic Group Behavioral Activation for Autistic Adults (GBAT)
3. august 2021 oppdatert av: Vanessa H. Bal, PhD, Rutgers, The State University of New Jersey
Adaptation of a Transdiagnostic Behavioral Activation Telehealth Group for Autistic Adults
The purpose of this study is to evaluate the feasibility, acceptability and effectiveness of a telehealth Group Behavioral Activation Therapy (GBAT) for autistic adults.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Detaljert beskrivelse
Detailed Description: This study is being done to demonstrate the feasibility, acceptability and effectiveness of a telehealth Group Behavioral Activation Therapy (GBAT) for autistic adults.
GBAT is intended to help adults manage stress, anxiety, down moods, and anger.
Similar programs have been shown to be effective in other contexts but has not yet been used for autistic adults or delivered via telehealth.
Because this is a new intervention, the investigators are interested in learning 1) whether GBAT can be done with autistic adults (feasibility), 2) what autistic adults think about GBAT (acceptability), and 3) whether GBAT is effective for helping autistic adults cope with their feelings.
Results from this study will be used to inform adaptation to the intervention and planning for future studies to further explore its effectiveness.
For this initial feasibility study, 8 autistic adults (18-40 years old) with VIQ and NVIQ>85, reading composite at least 6th grade level and elevated symptoms of depression, anxiety or anger will be recruited.
Studietype
Intervensjonell
Registrering (Faktiske)
6
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
New Jersey
-
Piscataway, New Jersey, Forente stater, 08854
- Rutgers University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 40 år (Voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Be 18-40 years old
- Have a confirmed diagnosis of Autism Spectrum Disorders (ASD).
- Have access to a device (e.g., computer with a webcam or smartphone) in order to complete online surveys and participate in the telehealth videoconferencing sessions
- *Have a VIQ and NVIQ of 85 or above
- *Have at least a 6th grade reading composite
- *Have elevated symptoms of depression, anxiety or anger. This will be determined based on scoring above the borderline or mild threshold on at least one of 3 screening measures (MINI; ASR; DASS-21).
Exclusion Criteria:
- Are younger than 18 years old, or older than 40 years old (Children are excluded because the focus is on adapting GBAT for adults; Individuals above 40 are excluded to restrict the adult focus to young adults that are more likely to be in similar life stages).
- Do not have an ASD diagnosis (because the study as the purpose of the current research is to examine GBAT's feasibility with autistic adults).
- Both VIQ and NVIQ below 85 OR less than 6th grade reading level
- Do not have elevated scores of depression, anxiety, or anger on the symptom screening measures.
- Are unable to understand English fluently (because the instruments being investigated are currently only validated in English and the intervention will be delivered in English).
- Are currently enrolled in another behavioral therapy or psychotherapy targeting depression,
- the PI's clinical judgment that it would not be in the adult's best interest to be enrolled (e.g., due to factors that may affect their engagement or comfort in the group).
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: GBAT
10-week behavioral activation treatment group.
|
This will be a modification of the Group Behavioral Activation Therapy program (Chu et al., 2009) for treatment of depression, anxiety and/or anger in autistic adults.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in symptoms on the Adult Self Report (ASR)
Tidsramme: 10 week study period; 4 week post-treatment
|
The ASR is a an assessment of adult psychopathology (e.g., anxiety, depression symptoms).
Most of the items are on a 3 point scale including: (0) Not true, (1) Somewhat or sometimes true, and (2) Very often or often true.
|
10 week study period; 4 week post-treatment
|
|
Change in Clinician Global Impairment rating
Tidsramme: 10 week study period;
|
The CGI is a 7 point scale on which the clinician rates the severity of the client's impairment.
The scale ranges from 1 (Normal, not at all ill) to 7 Extremely Ill; higher scores indicate more impairment.
|
10 week study period;
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in symptoms on the Depression Anxiety Stress Scales-21
Tidsramme: 10 week study period; 4 week post-treatment
|
The DASS-21 is a 21-item measure of depression and anxiety symptoms.
The measure produces scores in 3 domains: depression, anxiety, and stress.
The score ranges on each domain is from 0-42.
Higher scores on each domain indicate more impairment/ severity.
|
10 week study period; 4 week post-treatment
|
|
Change in distress on Patient Health Questionnaire (PHQ-9)
Tidsramme: 10 week study period
|
The PHQ-9, assessed weekly, is a 9-item questionnaire of psychological function over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale.
Total scores range from 0 to 27; higher scores reflect greater levels of depressive symptoms.
|
10 week study period
|
|
Change in anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)
Tidsramme: 10 week study period
|
The GAD-7, assessed weekly, is a 7-item questionnaire of anxiety symptoms over the past week with all items on a "0" (not at all) to "3"(nearly every day) scale.
Total scores range from 0 to 21; higher scores reflect greater levels of anxiety.
|
10 week study period
|
|
Change in Adaptive Behavior Assessment System - 3 (ABAS-3)
Tidsramme: 10 week study period
|
The ABAS-3 is a measure of adaptive function that yields age-standardized scores for three domains (Conceptual, Social and Practical) and an overall Global Adaptive Composite.
Each domain and the overall General Adaptive Composite result in a standard score, with a mean of 100 and a standard deviation of 15 (scores between 86 and 114 are considered "Average" on this instrument; scores under 70 are classified as "Extremely Low" relative to same aged peers).
Each domain is composed of several subdomains that yield scaled scale scores (Mean=10, SD=3), with scores between 7 and 13 falling in the "Average" range.
|
10 week study period
|
|
Change in Behavioral Activation for Depression Scale
Tidsramme: 10 week study period; 4 week post-treatment
|
The BADS is a 25-item measure designed to assess how clients become activated over the course of Behavior Activation treatment. There are 25 questions, each rated on a seven point scale ranging from 0 to 6. There are four subscales: AC = Activation subscale [score range 0 to 42] AR = Avoidance/Rumination subscale [score range 0-48] WS = Work/School Impairment subscale [score range 0-30] SI = Social Impairment subscale [score range 0-30] Higher scores indicate a better outcome on the Activation subscale. Higher scores indicate a worse outcome on the Avoidance/Rumination subscale, Work/School Impairment subscale, and Social Impairment subscale. |
10 week study period; 4 week post-treatment
|
|
Change in Idiographic target goals
Tidsramme: 10 week study period; 4 week post-treatment
|
Clients are asked to identify 3 goals they would like to accomplish.
There are no scores or scales.
Each goal is a statement shared by the client relevant to their own experiences.
Target goals are sensitive to change in treatment contexts.
|
10 week study period; 4 week post-treatment
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
16. februar 2021
Primær fullføring (Faktiske)
8. juli 2021
Studiet fullført (Faktiske)
8. juli 2021
Datoer for studieregistrering
Først innsendt
4. mars 2021
Først innsendt som oppfylte QC-kriteriene
4. mars 2021
Først lagt ut (Faktiske)
9. mars 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
5. august 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
3. august 2021
Sist bekreftet
1. august 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Pro2020001634
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .